Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BiosanaPharma
After earlier this year revealing that it had dropped a collaboration with BiosanaPharma on a biosimilar omalizumab rival to Xolair, Alvotech has now announced a fresh licensing deal for development and commercialization of a version from Kashiv BioSciences.
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.
Alvotech has delivered on indications that it would look to collaborate on certain biosimilar opportunities in future, striking a licensing deal with BiosanaPharma that will see the two firms partner to co-develop an omalizumab biosimilar rival to Xolair.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.